Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In vitro activity and single-step mutational analysis of rifamycin SV tested against enteropathogens associated with traveler's diarrhea and Clostridium difficile.

Antimicrobial agents and chemotherapy - 1 Mar 2011

Farrell David J, Putnam Shannon D, Biedenbach Douglas J, Moro Luigi, Bozzella Roberta, Celasco Giuseppe, Jones Ronald N

Abstract excerpt

Rifamycin SV is a broad-spectrum, poorly absorbed antimicrobial agent that, when coupled with MMX technology, is being targeted for the oral treatment of traveler's diarrhea (TD) and Clostridium difficile-associated disease (CDAD). Rifamycin SV was tested for activity against 911 TD-associated enteropathogens and 30 C. difficile isolates collected from several global surveillance studies. Rifamycin SV...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Bacterial Agents
Share to Clostridioides difficile

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Diarrhea

Share to Enterotoxigenic Escherichia coli

Share to Microbial Sensitivity Tests

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 21149623
DOI: 10.1128/AAC.00688-10
PMCID: PMC3067105

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In vitro activity and single-step mutational analysis of rifamycin SV tested against enteropathogens associated with traveler's diarrhea and Clostridium difficile.PMID 21149623Read ↗

Spectrum of activity and mode of action of REP3123, a new antibiotic to treat Clostridium difficile infectionsSemantic proximity Read ↗

Antibacterials Developed to Target a Single Organism: Mechanisms and Frequencies of Reduced Susceptibility to the Novel Anti-Clostridium difficile Compounds Fidaxomicin and LFF571.Semantic proximity Read ↗

In vitro activity of surotomycin against contemporary clinical isolates of toxigenic Clostridium difficile strains obtained in Spain.Semantic proximity Read ↗

Rifaximin resistance in Clostridioides difficile is associated with specific rpoB alleles and multilocus sequence typing (MLST) clades.Semantic proximity Read ↗

Hypervirulent Clostridium difficile PCR-Ribotypes Exhibit Resistance to Widely Used DisinfectantsSemantic proximity Read ↗

In Vitro Activity of the Ultrabroad-Spectrum-Beta-Lactamase Inhibitor QPX7728 against Carbapenem-Resistant Enterobacterales with Varying Intrinsic and Acquired Resistance MechanismsSemantic proximity Read ↗

Characterization of a clinical Clostridioides difficile isolate with markedly reduced fidaxomicin susceptibility and a V1143D mutation in rpoBSemantic proximity Read ↗

<i>In Vitro</i> Activity of Fidaxomicin (OPT-80) Tested against Contemporary Clinical Isolates of <i>Staphylococcus</i> spp. and <i>Enterococcus</i> sppSemantic proximity Read ↗

In vitro biological evaluation of novel broad-spectrum isothiazolone inhibitors of bacterial type II topoisomerases.Semantic proximity Read ↗

In vitro selection, via serial passage, of Clostridium difficile mutants with reduced susceptibility to fidaxomicin or vancomycin.Semantic proximity Read ↗

High-throughput screening and whole genome sequencing identifies an antimicrobially active inhibitor of Vibrio cholerae.Semantic proximity Read ↗

Resistance to moxifloxacin in toxigenic Clostridium difficile isolates is associated with mutations in gyrA.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.